Bora Kim

Bora Kim

Auto-generated profile, based on publicly available information

Bora Kim

Division of Hematology-Oncology, Department of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon, Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
SLSung Hee Lim
Sung Hee Lim
HKHan Jo Kim
Han Jo Kim
SKSe Hyung Kim
Se Hyung Kim
SCSeong Hyeok Choi
Seong Hyeok Choi
BKBora Kim
Bora Kim
JYJina Yun
Jina Yun
Lim SH, et al. J Korean Med Sci. 2023 Mar;38(13):e103. https://doi.org/10.3346/jkms.2023.38.e103

1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
SLSung Hee Lim
Sung Hee Lim
SCSeong Hyeok Choi
Seong Hyeok Choi
JKJi Youn Kim
Ji Youn Kim
BKBora Kim
Bora Kim
HKHan Jo Kim
Han Jo Kim
JYJina Yun
Jina Yun
Lim SH, et al. J Korean Med Sci. 2023 Apr;38(18):e139. https://doi.org/10.3346/jkms.2023.38.e139

21 August 2025 in Clinics
Verified
Journal Article
Open access
JYJina Yun
Jina Yun
BKBora Kim
Bora Kim
HKHyuk Kim
Hyuk Kim
SLSung Hee Lim
Sung Hee Lim
SCSeong Hyeok Choi
Seong Hyeok Choi
SPSeong Kyu Park
Seong Kyu Park
Despite the availability of bivalent vaccines targeting both the ancestral SARS-CoV-2 strain and Omicron subvariants, vaccination rates remain low in South Korea. This study aims to evaluate the neutralizing activity against Omicron subvariants following the third SARS-CoV-2 vaccination in patients undergoing chemotherapy, as well as to assess the need for additional vaccinations. Between April and November 2022, the authors assessed the neutralizing activity of the third SARS-CoV-2 vaccine dose in 63 patients undergoing chemotherapy using an ELISA-based surrogate Virus Neutralization Test (sVNT). The authors examined the influence of factors such as prior COVID-19 infection, cancer type (solid vs. hematologic malignancy), type of chemotherapy regimen (cytotoxic chemotherapy, targeted therapy, immune checkpoint inhibitors), and vaccine type (homologous vector, homologous mRNA, heterologous) on neutralizing activity. Among the 57 patients included in the analysis, 26 (45.6 %) had a history of SARS-CoV-2 infection. Patients with hematologic cancers exhibited lower neutralizing antibody responses compared to those with solid tumors for Omicron subvariants BA.1 (24.44 % vs. 71.68 %, p = 0.020), BA.2 (48.22 % vs. 94.59 %, p = 0.006), and BA.4/5 (24.76 % vs. 78.06 %, p = 0.046). Among uninfected patients (n = 31), sVNT inhibition scores were significantly lower across all subvariants (e.g., 5.89 % for BA.1 vs. 58.11 % in infected, p = 0.0025). Treatment delays due to infection were observed in 9 patients (17.75 days on average). Although no deaths were directly attributed to infection, one patient died due to disease progression following a treatment delay caused by the infection. Patients undergoing chemotherapy displayed weak neutralizing responses against Omicron subvariants, especially those with hematologic cancers or no prior infection. Consequently, it is crucial to actively recommend additional vaccinations with bivalent or newly developed vaccines for these vulnerable patients.